14 results about "Drug side effects" patented technology

This invention application provides compositions containing red yeast rice pigment and their applications, compositions with α-glucosidase inhibitory activity and their applications, and further, their application in α-glucosidase inhibitors, belonging to the technical field of natural active compounds inhibiting α-glucosidase. The compositions of this invention comprise one or both of red yeast rice pigment and red yeast rice pigment: wherein the molar ratio of acarbose to red yeast rice pigment is 400:400-600:300; the molar ratio of acarbose to red yeast rice pigment is 400:200-600:150; and the molar ratio of red yeast rice pigment to red yeast rice pigment is 150:400-200:300. The compositions involved in this invention have a significant synergistic inhibitory effect on α-glucosidase, superior to using the above compounds alone, and can achieve reduced drug dosage and reduced drug side effects.

The application belongs to the technical field of biological medicine, and particularly relates to application of an active component of chamomile in preparation of an asthma treatment preparation. The chamomile active component is prepared by the following method: chamomile is subjected to reflux extraction with ethanol as an extraction solvent to obtain an extract; the extract is purified, eluted with water and ethanol in sequence, and the eluate of ethanol is collected and dried to obtain the chamomile active component. The chamomile active component provided in the application can regulate autophagy and apoptosis through multiple targets, inhibit airway inflammation, and improve immune imbalance, and can not only effectively relieve asthma symptoms, but also reduce airway epithelial damage and inhibit airway remodeling, thereby overcoming the defects of existing drugs, such as large side effects, limited efficacy on severe and hormone-resistant asthma patients, and difficulty in reversing airway damage. The active component is derived from a natural plant, is safe, and has a good application prospect in preparation of asthma treatment drugs.

This invention relates to the field of hair growth composition technology, specifically to an anti-hair loss and hair growth composition and its application in hair growth products. The active ingredients of the composition include GHK-Gu and Erigeron tiglium extract, and preferably also include Eclipta prostrata extract. Through in-depth research, this invention has for the first time discovered that GHK-Gu and Erigeron tiglium extract can produce a synergistic effect at a specific ratio. Based on this, a ternary compound system containing Eclipta prostrata extract was optimized. The composition significantly improves hair density, diameter, and color through multi-target synergistic effects, including inhibiting 5α-reductase activity, promoting dermal papilla cell proliferation, and activating tyrosinase. This invention solves the technical problems of significant side effects from existing chemical drugs and complex compositions of traditional Chinese medicine compound formulas, providing a highly efficient, safe, and simplified solution for hair loss treatment. In vitro and in vivo experiments have confirmed its significant anti-hair loss, hair growth, and hair darkening effects.

The application belongs to the technical field of medicine, and discloses application of a sesquiterpenoid compound in preparation of a drug for regulating synovial cells. The application first discloses a triple regulation mechanism of CJB on fibroblast-like synovial cells, i.e. inhibiting cell proliferation, reducing inflammatory reaction, and regulating ferroptosis pathway. Compared with a single-target drug, the multi-target effect mode can more comprehensively control the pathological process of RA, not only inhibits abnormal proliferation of FLS and secretion of inflammatory factors, but also removes pathological synovial cells by regulating ferroptosis and apoptosis, significantly improves the treatment effect, and reduces disease recurrence. Moreover, CJB has low toxicity, raw materials are easy to obtain, and can be used in combination with existing anti-rheumatic drugs, thereby reducing drug side effects and treatment costs.

The application discloses a kind of construction methods of diabetic nephropathy combined with acute kidney injury rabbit comorbidity model, it is related to biological medicine technical field, the construction method includes the following steps: rabbit is fed with high-fat high-sugar feed, then injection tetraoxypyrimidine, constructs type 2 diabetes rabbit model, continue to feed high-fat high-sugar feed, detect rabbit blood sugar, blood fat and urine albumin / creatinine ratio, carries out pathological examination of kidney tissue, determines whether the diabetic nephropathy rabbit model is established successfully, to the diabetic nephropathy rabbit model that is successfully constructed injection folic acid-sodium bicarbonate solution, detect blood urea and creatinine level, carry out pathological examination of kidney tissue, determine whether the diabetic nephropathy combined with acute kidney injury rabbit comorbidity model is successfully constructed.The application provides effective animal model for the pathogenesis and new treatment target of diabetic comorbidity, effectively solves the problem that single animal model cannot comprehensively reflect complex disease and the influence of drug side effects on experimental animals.

The application relates to the technical field of physical massage, in particular to a hand pinching type pressure relaxation device which comprises a silica gel bottom shell, the top end of the silica gel bottom shell is integrally formed with a silica gel shell, and the silica gel shell is externally covered with a covering layer made of mark acupoint polyester fiber material; a hard PVC material grabbing part is arranged on the top end of the silica gel shell. The device is provided with a temperature control mechanism, cooperates with visual acupoint meridian marks, can be accurately positioned with internal massage convex contacts, realizes low-threshold fixed-point acupoint massage, adopts a full passive working mechanism, uses hand pinching mechanical energy as the only energy source, and can be used for improving menopausal hot flashes, cold intolerance and other uncomfortable symptoms; the device can realize the differential massage effect of hot compress deep pressing and cold compress surface relaxing, does not need a battery and an external power supply, is light in overall structure, convenient to use and portable, adopts a pure physical physiotherapy mode, has no drug side effects, is high in safety, and is suitable for daily long-term maintenance of menopausal people.

This invention discloses a composition with weight-loss effects, relating to the fields of functional foods, health foods, or pharmaceuticals. The composition with weight-loss effects is prepared from components comprising the following parts by weight: 10-30 parts of Fat Burner™ Moroccan Cardamom Extract, 5-20 parts of Gingerol, 15-40 parts of Green Tea Extract, 20-50 parts of L-Carnitine, 30-60 parts of Dietary Fiber, 10-30 parts of Auxiliary Ingredients, and 1-10 parts of Lipid Metabolism Activator. This invention leverages the synergistic advantages of multi-target activation of fat metabolism, reduction of energy intake, and improvement of metabolic health, effectively overcoming the limitations of existing technologies such as insufficient synergistic effects of natural weight-loss ingredient combinations, limited fat metabolism promotion effects, and significant side effects of chemical drugs.

This invention discloses a nucleic acid delivery vector, its preparation method, and its applications, belonging to the field of drug delivery vector technology. The nucleic acid delivery vector provided by this invention is based on the LNP structure, retaining key lipids or lipid-like substances unchanged. By altering the surface composition of the LNP, it can effectively reduce the accumulation of LNP in the liver, achieving effective in-situ mRNA delivery and protein expression; thereby significantly improving LNP organ toxicity, reducing mRNA drug side effects, and enhancing mRNA drug tolerance; it achieves in-situ targeting and high nucleic acid expression by promoting in-situ uptake of the vector and enhancing endosome escape; by optimizing various components and parameters or adding active lipids, the in-situ expression level and stability of the prepared nucleic acid delivery vector can be enhanced; after use, sonication of the application site can also promote the in-situ expression level of the nucleic acid delivery vector.

This invention relates to the field of microbial technology, and in particular to a short-fermenting Lactobacillus strain capable of significantly preventing the progression of kidney disease and stabilizing renal function, and its uses. The strain of this invention has shown good efficacy in various kidney disease models, especially in a cisplatin-induced CKD model, significantly alleviating weight loss induced by platinum-based drugs in mice; it also provides excellent protection against platinum-based drug-induced intestinal inflammation and intestinal wall integrity; in the long term, it significantly alleviates platinum-based drug nephrotoxicity; it has a good stabilizing effect on renal function and can effectively prevent the progression of CKD. Therefore, the described strain can be used to prepare pharmaceutical compositions for stabilizing and improving renal function in acute and chronic kidney diseases, and can also be used to prepare drugs that reduce drug side effects, showing very broad application prospects.

This invention belongs to the field of drug synthesis, specifically relating to a mitochondrial-targeted chlordamine and cinnamaldehyde conjugated prodrug, its preparation method, and its application. The structural formula of the chlordamine and cinnamaldehyde conjugated prodrug is as follows. This invention provides a mitochondrial-targeted chlordamine and cinnamaldehyde conjugated prodrug that, through triphenylphosphine targeting mitochondria, delivers cinnamaldehyde and chlordamine to tumor cells, causing mitochondrial dysfunction and inhibiting tumor cell growth. By introducing various substituents onto the aromatic ring, the spatial conformation of the molecule is improved, enhancing its activity. Chlordamine acts on mitochondria, affecting mitochondrial energy metabolism; through triphenylphosphine targeting tumor cells and synergistic action with cinnamaldehyde, it reduces the side effects of anticancer drugs.

This application relates to the field of biomedicine. Specifically, this application relates to *Lactobacillus paracasei*, compositions comprising the same, pharmaceutical compositions and cultures thereof, and uses thereof. The *Lactobacillus paracasei* of this application not only synergistically enhances the antitumor efficacy of paclitaxel but also effectively alleviates drug side effects, reverses tumor drug resistance, and exerts comprehensive probiotic effects by regulating gut microbiota and the immune microenvironment, demonstrating promising application prospects.

This application provides a method, apparatus, and device for identifying target drugs for predetermined tissues, relating to the field of bioinformatics. The method includes: acquiring multiple candidate drugs for a predetermined disease; identifying all target genes for each candidate drug; identifying quantitative trait gene loci (CTTLs) of target gene expression in a predetermined tissue based on all target genes; using these CTTLs as genetic instrumental variables and employing Mendelian randomization analysis, determining the potential causal relationship between the expression of the combined target genes of the candidate drugs in the predetermined tissue and the predetermined disease; and identifying the target drug for the predetermined tissue based on the potential causal relationship. This method can clearly identify the potential tissue type for drug action, effectively identify target drugs for predetermined tissues, improve the targeting of drug therapy, and reduce drug side effects.

This invention relates to the field of surgical wound treatment materials and related instruments, and discloses an injectable hydrogel and injection method for wounds after tophi removal surgery, comprising a thermosensitive hydrogel matrix, a uric acid-lowering active ingredient, and an anti-inflammatory active ingredient; the thermosensitive hydrogel matrix is ​​selected from one or more of polylactic acid-polyethylene glycol-polylactic acid block copolymer, polylactic acid-glycolic acid copolymer-polyethylene glycol-polylactic acid-glycolic acid copolymer block copolymer, and poloxamer 407; the mass percentage concentration of the thermosensitive hydrogel matrix in the injectable hydrogel for wounds after tophi removal surgery is 15%-30%. Compared with existing oral or intravenous systemic drug administration regimens, the local sustained-release drug administration method of this invention avoids systemic drug side effects and improves the local drug utilization efficiency of the surgical cavity.